

ULTRALIFE CORP
Form 8-K
October 25, 2018

**UNITED
STATES
SECURITIES
AND
EXCHANGE
COMMISSION
Washington, D.C.
20549**

FORM 8-K

**CURRENT
REPORT**

**Pursuant to
Section 13 or
15(d) of the
Securities
Exchange Act of
1934**

Date of Report
(Date of the earliest
event reported)

October 24, 2018

**ULTRALIFE
CORPORATION**
(Exact name of
registrant as
specified in its
charter)

Delaware **000-20852** **16-1387013**
(State of incorporation) (Commission File Number)

(IRS
Employer
Identification
No.)

2000
Technology
Parkway, 14513
Newark,
New York
(Address of
principal
executive (Zip Code)
offices)

(315) 332-7100
(Registrant's
telephone number,
including area code)

Check the
appropriate box
below if the Form
8-K filing is
intended to
simultaneously
satisfy the filing
obligation of the
registrant under any
of the following
provisions (see
General Instruction
A.2. below):

☐ Written
communications
pursuant to Rule
425 under the
Securities Act (17
CFR 230.425)

☐ Soliciting
material pursuant to
Rule 14a-12 under
the Exchange Act
(17 CFR
240.14a-12)

☐
Pre-commencement
communications
pursuant to Rule
14d-2(b) under the
Exchange Act (17
CFR 240.14d-2(b))

☐
Pre-commencement
communications
pursuant to Rule
13e-4(c) under the
Exchange Act (17
CFR 240.13e-4(c))

Indicate by check
mark whether the
registrant is an
emerging growth
company as defined
in Rule 405 of the
Securities Act of
1933 or Rule 12b-2
of the Securities
Exchange Act of
1934. Emerging
growth company ☐

If an emerging
growth company,
indicate by check
mark if the
registrant has
elected not to use
the extended
transition period for
complying with any
new or revised
financial accounting
standards provided
pursuant to Section
13(a) of the
Exchange Act. ☐

Item 8.01 Other Events

In a press release dated October 24, 2018, Ultralife Corporation (NASDAQ: ULBI) announced that it has received a fixed price, indefinite-delivery/indefinite-quantity contract for purchases not to exceed \$9.5 million from an undisclosed major defense prime contractor for vehicle communications kits for use by the U.S. Department of Defense. The award is for one year with four option years with the amounts and timing of deliveries based on program requirements. Initial deliveries under this contract are expected to begin in 2019.

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(d) Exhibits

Exhibit Number	Description
-------------------	-------------

99.1	<u>Press Release of Ultralife Corporation dated October 24, 2018</u>
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ULTRALIFE CORPORATION

October 24, 2018 By: /s/ Philip A. Fain
Chief Financial Officer and Treasurer